[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614465":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Arn Migowski Rocha dos Santos","Instituto Nacional de Câncer","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[20],{"facility":21,"status":7,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Research Site","Rio de Janeiro","20230-130","Brazil","BR",{"type":27,"coordinates":28},"Point",[29,30],-43.18223,-22.90642,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100614465","lung-cancer-screening-implementation-project-in-the-brazilian-public-health-care-system-lusip-100614465",false,"NCT07279948","Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)","LUSIP","Inclusion Criteria:\n\nIn order, to be eligible for the study, patients must fulfill all the following inclusion criteria:\n\n* Age between ≥50 and ≤80 years.\n* Be a current smoker or have quit 15 years ago or less.\n* Have participated or are currently participating in smoking cessation program.\n* Lifetime smoking exposure equal to or greater than 20 pack-year.\n* Provided signed informed consent (ICF)\n\nExclusion Criteria:\n\n* In order, to be exclude for the study, patients must at least one of the following exclusion criteria:\n\n  * Contraindications to the screening examination: (claustrophobic or weighing more than 130 kgs).\n  * Inability to climb 3 stair steps non-stop (36 steps).\n  * Disabling dyspnea\n  * Symptomatic (with signs and symptoms suspicious of breast cancer lung, namely):\n\n    * pleuritic chest pain\n    * rapidly progressive dyspnea of recent onset\n    * hemoptysis\n    * unexplained hoarseness, lasting more than 1 month.\n    * bone pain\n    * supraclavicular lymphadenopathy or cervical lymphadenopathy persistent\n    * unexplained weight loss of 5% or more of weight in less than 6 months\n    * Previous history of malignant neoplasm (excluding non-melanoma skin cancer) diagnosed less than 10 years before the date of the interview;\n    * Patients with diagnostic of severe psychiatric disease\n    * Immunosuppressed by illness or drugs.\n    * Subjected to anterior lung resection even when determined due to an etiology other than malignant neoplasia.\n    * Person with a serious terminal illness that contraindicates curative lung surgery.","ALL","50 Years","80 Years",{"count":45,"type":46},477,"ESTIMATED","OBSERVATIONAL","A prospective, longitudinal, single-arm interventional study of lung cancer screening.",[50],"Lung Cancer","NOT_YET_RECRUITING","2026-06-22",{"date":54,"type":55},"2026-06-25","ACTUAL",{"date":57,"type":46},"2026-06-30",{"date":59,"type":46},"2027-01-31",{"name":5,"class":6},1]